Alchemab Targets ‘List Of The Worst-Served Diseases’
Biotech Raises $82m In Series A Financing
In an exclusive interview, Alchemab CEO Alex Leech talks to In Vivo about the company’s method of identifying naturally occurring antibodies to target high unmet needs in oncology, neurodegeneration and infectious diseases.
